Exelixis Shares Fall After FDA Pushes Zanzalintinib Review to 2027

Exelixis shares declined after the U.S. Food and Drug Administration (FDA) extended the review period for its zanzalintinib combination therapy by three months. The delay follows the company's submission of an amendment containing updated safety and efficacy data, which shifted the regulatory timeline for the treatment of metastatic colorectal cancer.

"While we are surprised by the three-month delay, we believe the risk of rejection remains low, given that the combination of zanzalintinib plus Tecentriq demonstrated an overall survival (OS) benefit across the intent-to-treat population in the Phase 3 STELLAR-303 study," said William Blair analyst Andy Hsieh in a research note.

Updated Regulatory Timeline

According to an SEC filing submitted by the company, the new Prescription Drug User Fee Act (PDUFA) action date is March 3, 2027. The FDA classifies the submission of additional data late in a review cycle as a major amendment. This classification triggers an automatic extension of the review clock to allow regulators time to evaluate the new information.

Clinical Context and Market Impact

The therapy under review is a combination of zanzalintinib and atezolizumab, marketed as Tecentriq. The STELLAR-303 trial serves as the primary clinical evidence for the application, focusing on patients with previously treated metastatic colorectal cancer.

A PDUFA date extension is a procedural mechanism used by the FDA to ensure that supplemental data, such as extended follow-up results or updated safety profiles, is integrated into the existing review. While the market often reacts to timeline shifts due to uncertainty regarding commercial launch dates, analysts continue to monitor the clinical data presented in the trial results.

What Is at Stake

For Exelixis, the approval of zanzalintinib represents an expansion of its oncology portfolio. The company is transitioning from its established tyrosine kinase inhibitor business to a pipeline of newer therapies. The outcome of the FDA review will determine the company's ability to enter the metastatic colorectal cancer market, where existing standard-of-care options have shown limited success in improving overall survival rates compared to newer targeted combinations.